SPDR S&P Pharmaceuticals ETF
XPH
XPH
85 hedge funds and large institutions have $205M invested in SPDR S&P Pharmaceuticals ETF in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
21% more funds holding
Funds holding: 70 → 85 (+15)
5.93% more ownership
Funds ownership: 45.71% → 51.63% (+5.9%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
85
Holding in Top 10
–
Calls
$1.14M
Puts
$316K
Top Buyers
| 1 | +$15.9M | |
| 2 | +$14.3M | |
| 3 | +$7.54M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$5.55M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.13M |
Top Sellers
| 1 | -$12.1M | |
| 2 | -$6.45M | |
| 3 | -$2.34M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.82M |
| 5 |
VF
Virtu Financial
New York
|
-$1.5M |